You are here
Simvastatin in patients with progressive multiple sclerosis
Johann Auer , Robert Berent
The Lancet, Volume 384, Issue 9947, 13–19 September 2014, Pages 951–952
We read with great interest the study by Jeremy Chataway and colleagues (June 28, p 2213)1 who reported that in patients with secondary progressive multiple sclerosis, high-dose simvastatin might reduce the rate of whole-brain atrophy compared with placebo. In this phase 2 trial, treatment with high-dose simvastatin was well tolerated and safe.